Lymphocyte surface molecules as immune activation biomarkers

Clinical Biochemistry

Volumn 49, Issue 4-5, 2016, Pages 347-354

  Wieland, Eberhard ^a   Shipkova, Maria ^a  

^a KLINIKUM STUTTGART   (Germany)

Author keywords

Biomarkers; Cell function assays; Flow cytometry; Immunosuppression; T cell activation; Transplantation

Indexed keywords

BIOLOGICAL MARKER; CD134 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD38 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD71 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL PEPTIDASE IV; FAS ANTIGEN; FAS LIGAND; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DIAGNOSTIC KIT; LEUKOCYTE ANTIGEN;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE STATUS; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC KIT; IMMUNOLOGY; METABOLISM;

ANTIGENS, CD; BIOMARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOCYTES; REAGENT KITS, DIAGNOSTIC;

EID: 84959457984     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.07.099     Document Type: Article

References (87)

1. Moreau A., Varey E., Anegon I., Cuturi M. Effector mechanisms of rejection. Cold Spring Harb. Perspect. Biol. 2013, 3.
2. Li X.C., Kloc M., Ghobrial R.M. Memory T cells in transplantation - progress and challenges. Curr. Opin. Organ Transplant. 2013, 18:387-392.
3. Stegall M.D., Gloor J.M. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr. Opin. Organ Transplant. 2010, 15:8-10.
4. Le Moine A., Vokaer B., Charbonnier L.M. A brief focus on memory cells in transplantation. Transplant. Proc. 2009, 41:3361-3362.
5. Shipkova M., Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin. Chim. Acta 2012, 413:1338-1349.
6. Kitchens W.H., Uehara S., Chase C.M., Colvin R.B., Russell P.S., Madsen J.C. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006, 81:811-817.
7. Boleslawski E., Othman S.B., Aoudjehane L., Chouzenoux S., Scatton O., Soubrane O., et al. CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long-term survivors after liver transplantation. Liver Transpl. 2011, 17:299-305.
8. Wieland E., Shipkova M., Martius Y., Hasche G., Klett C., Bolley R., et al. Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. Ther. Drug Monit. 2011, 33:341-349.
9. Minguela A., Miras M., Bermejo J., Sanchez-Bueno F., Lopez-Alvarez M.R., Moya-Quiles M.R., et al. HBV and HCV infections and acute rejection differentially modulate CD95 and CD28 expression on peripheral blood lymphocytes after liver transplantation. Hum. Immunol. 2006, 67:884-893.
10. Davis B.H., Wood B., Oldaker T., Barnett D. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims. Cytometry B Clin. Cytom. 2013, 84:282-285.
11. Davis B.H., Dasgupta A., Kussick S., Han J.Y., Estrellado A. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues. Cytometry B Clin. Cytom. 2013, 84:286-290.
12. Shipkova M., Millán O., Picard N., Noceti O., Sommerer C., Christians U., Wieland E. Analytical aspects of the implementation of biomarkers in clinical transplntation. Ther. Drug Monit. 2015, Epub ahead of print.
13. Favaloro E.J. Differential expression of surface antigens on activated endothelium. Immunol. Cell Biol. 1993, 71:571-581.
14. Stalder M., Birsan T., Holm B., Haririfar M., Scandling J., Morris R.E. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther. Drug Monit. 2003, 25:22-27.
15. Premaud A., Rousseau A., Johnson G., Canivet C., Gandia P., Muscari F., et al. Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. Pharmacol. Res. 2011, 63:432-438.
16. Kamar N., Glander P., Nolting J., Bohler T., Hambach P., Liefeldt L., et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin. J. Am. Soc. Nephrol. 2009, 4:936-942.
17. Barten M.J., Tarnok A., Garbade J., Bittner H.B., Dhein S., Mohr F.W., et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif. 2007, 40:50-63.
18. Beik A.I., Morris A.G., Higgins R.M., Lam F.T. Serial flow cytometric analysis of T-cell surface markers can be useful in differential diagnosis of renal allograft dysfunction. Clin. Transpl. 1998, 12:24-29.
19. Lun A., Cho M.Y., Muller C., Staffa G., Bechstein W.O., Radke C., et al. Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation. Clin. Chim. Acta 2002, 320:69-78.
20. Vondran F.W., Timrott K., Kollrich S., Steinhoff A., Kaltenborn A., Schrem H., et al. Pre-transplant immune state defined by serum markers and alloreactivity predicts acute rejection after living donor kidney transplantation. Clin. Transpl. 2014, 28:968-979.
21. Deng M.C., Erren M., Roeder N., Dreimann V., Gunther F., Kerber S., et al. T-cell and monocyte subsets, inflammatory molecules, rejection, and hemodynamics early after cardiac transplantation. Transplantation 1998, 65:1255-1261.
22. Berg M., Zavazava N. Regulation of CD28 expression on CD8+ T cells by CTLA-4. J. Leukoc. Biol. 2008, 83:853-863.
23. Boleslawski E., Conti F., Sanquer S., Podevin P., Chouzenoux S., Batteux F., et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004, 77:1815-1820.
24. Minguela A., Marin L., Torio A., Muro M., Garcia-Alonso A.M., Moya-Quiles M.R., et al. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum. Immunol. 2000, 61:658-669.
25. Ziegler S.F., Ramsdell F., Alderson M.R. The activation antigen CD69. Stem Cells 1994, 12:456-465.
26. Tugulea S., Ciubotariu R., Colovai A.I., Liu Z., Itescu S., Schulman L.L., et al. New strategies for early diagnosis of heart allograft rejection. Transplantation 1997, 64:842-847.
27. Mehrotra A., Levendahl J., Purroy C., Cravedi P. Monitoring T cell alloreactivity. Transplant. Rev. (Orlando) 2015, 29:53-59.
28. Lindsey W.B., Lowdell M.W., Marti G.E., Abbasi F., Zenger V., King K.M., et al. CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy 2007, 9:123-132.
29. Ekong U.D., Luo X., Yu M., Wang D., Miller S.D., O'Gorman Maurice R.G. Lymphocyte activation markers may predict the presence of donor specific alloreactivity in pediatric living related liver transplant recipients. Hum. Immunol. 2011, 72:392-397.
30. Posselt A.M., Vincenti F., Bedolli M., Lantz M., Roberts J.P., Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation 2003, 76:190-195.
31. Schuurman H.J., van Wichen D., de Weger R.A. Expression of activation antigens on thymocytes in the 'common thymocyte' stage of differentiation. Thymus 1989, 14:43-53.
32. Böhler T., Nolting J., Kamar N., Gurragchaa P., Reisener K., Glander P., et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther. Drug Monit. 2007, 29:77-86.
33. Van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
34. Frentsch M., Arbach O., Kirchhoff D., Moewes B., Worm M., Rothe M., et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat. Med. 2005, 11:1118-1124.
35. Rijen Van, Miranda M.L., Metselaar H.J., Hommes M., Ijzermans Jan N.M., Tilanus H.W., Kwekkeboom J. Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumor necrosis factor-receptor superfamily costimulatory molecules. Immunology 2003, 109:109-116.
36. Ashokkumar C., Talukdar A., Sun Q., Higgs B.W., Janosky J., Wilson P., et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am. J. Transplant. 2009, 9:179-191.
37. Sindhi R., Ashokkumar C., Higgs B.W., Gilbert P.B., Sun Q., Ranganathan S., et al. Allospecific CD154+ T-cytotoxic memory cells as potential surrogate for rejection risk in pediatric intestine transplantation. Pediatr. Transplant. 2012, 16:83-91.
38. Ashokkumar C., Shapiro R., Tan H., Ningappa M., Elinoff B., Fedorek S., et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. Transplantation 2011, 92:433-438.
39. Wieland E., Olbricht C.J., Süsal C., Gurragchaa P., Böhler T., Israeli M., et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther. Drug Monit. 2010, 32:560-572.
40. Boleslawski E., BenOthman S., Grabar S., Correia L., Podevin P., Chouzenoux S., et al. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin. Transpl. 2008, 22:494-501.
41. Wang Y., Liu Y., Han R., Li Q., Yao Z., Niu W., et al. Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation. J. Gastroenterol. Hepatol. 2010, 25:138-142.
42. Effros R.B., Dillard L., Zeller E., Naeim F., Walford R.L. Strong HLA-DR expression in T cell cultures after activation is necessary for IL-2-dependent proliferation. Hum. Immunol. 1983, 8:249-254.
43. Alvarez C.M., Paris S.C., Arango L., Arbelaez M., Garcia L.F. Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation. Transplantation 2004, 78:1541-1547.
44. Kosmaczewska A., Magott-Procelewska M., Frydecka I., Ciszak L., Bocko D., Szteblich A., et al. CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: a relationship with post-transplantation clinical course. Transpl. Immunol. 2006, 16:32-40.
45. Saxena A., Panigrahi A., Gupta S., Dinda A.K., Guleria S., Thakur B., et al. Frequency of T cell expressing Th1 and Th2 associated chemokine receptor in patients with renal allograft dysfunction. Transplant. Proc. 2012, 44:290-295.
46. Sindhi R., Allaert J., Gladding D., Haaland P., Koppelman B., Dunne J., et al. Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses - potential clinical implications. J. Immunol. Methods 2003, 272:257-272.
47. Berry V., Magill A., Yost M., Janosky J., Sindhi R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 2006, 69:95-103.
48. Barten M.J., Dhein S., Chang H., Bittner H.B., Tarnok A., Rahmel A., et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J. Immunol. Methods 2003, 283:99-114.
49. Hoerning A., Kohler S., Jun C., Lu J., Fu J., Tebbe B., et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clin. Exp. Immunol. 2012, 168:251-259.
50. Hueso M., Mestre M., Benavente Y., Bas J., Grinyó J.M., Navarro E. Pretransplant low CD3 + CD25high cell counts or a low CD3 + CD25high/CD3 + HLA-DR+ ratio are associated with an increased risk to acute renal allograft rejection. Transplantation 2011, 92:536-542.
51. Süsal C., Dohler B., Sadeghi M., Salmela K.T., Weimer R., Zeier M., et al. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011, 91:1364-1369.
52. Schade R.P., Van Ieperen-Van DiJk A.G., Versluis C., Van Reijsen F.C., Kimpen J.L., Bruijnzeel-Koomen C.A., et al. Cell-surface expression of CD25, CD26, and CD30 by allergen-specific T cells is intrinsically different in cow's milk allergy. J. Allergy Clin. Immunol. 2002, 109:357-362.
53. Süsal C., Opelz G. Posttransplant sCD30 as a biomarker to predict kidney graft outcome. Clin. Chim. Acta 2012, 413:1350-1353.
54. Velasquez S.Y., Garcia L.F., Opelz G., Alvarez C.M., Süsal C. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-gamma and IL-2. Transplantation 2013, 96:154-161.
55. Cravedi P., Heeger P.S. Immunologic monitoring in transplantation revisited. Curr. Opin. Organ Transplant. 2012, 17:26-32.
56. Süsal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J. Am. Soc. Nephrol. 2002, 13:1650-1656.
57. Pelzl S., Opelz G., Wiesel M., Schnulle P., Schonemann C., Dohler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3-6.
58. Pelzl S., Opelz G., Daniel V., Wiesel M., Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
59. Grenzi P.C., Campos É.F., Tedesco-Silva H., Felipe C.R., Franco M.F., Soares M.F., et al. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy. Transpl. Immunol. 2013, 29:34-38.
60. Weimer R., Susal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am. J. Transplant. 2006, 6:1865-1874.
61. Kovac J., Arnol M., Vidan Jeras B., Bren A.F., Kandus A. Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation. Transplant. Proc. 2010, 42:4043-4046.
62. Chen Y., Tai Q., Hong S., Kong Y., Shang Y., Liang W., et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation 2012, 94:911-918.
63. Halim M.A., Al-Otaibi T., Al-Muzairai I., Mansour M., Tawab K.A., Awadain W.H., et al. Serial soluble CD30 measurements as a predictor of kidney graft outcome. Transplant. Proc. 2010, 42:801-803.
64. Altermann W., Schlaf G., Rothhoff A., Seliger B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrol. Dial. Transplant. 2007, 22:2795-2799.
65. Valke Lars L.F.G., van Cranenbroek B., Hilbrands L.B., Joosten I. Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation. Transpl. Immunol. 2015, 32:18-22.
66. Spiridon C., Nikaein A., Lerman M., Hunt J., Dickerman R., Mack M. CD30, a marker to detect the high-risk kidney transplant recipients. Clin. Transpl. 2008, 22:765-769.
67. Nikaein A., Spiridon C., Hunt J., Rosenthal J., Anderson A., Eichhorn E., et al. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clin. Transpl. 2007, 21:744-747.
68. Shah A.S., Leffell M.S., Lucas D., Zachary A.A. Elevated pretransplantation soluble CD30 is associated with decreased early allograft function after human lung transplantation. Hum. Immunol. 2009, 70:101-103.
69. Ypsilantis E., Key T., Bradley J.A., Morgan C.H., Tsui S., Parameshwar J., et al. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome. J. Heart Lung Transplant. 2009, 28:1206-1210.
70. Kim K.H., Oh E., Jung E., Park Y., Choi J.Y., Kim D., et al. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection. Transplant. Proc. 2006, 38:1429-1431.
71. Mehta R., Shah G., Adler W., Kittur D. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients. Clin. Transpl. 2004, 18(Suppl. 12):67-71.
72. Panigrahi A., Deka R., Bhowmik D., Dash S.C., Tiwari S.C., Guleria S., et al. Functional assessment of immune markers of graft rejection: a comprehensive study in live-related donor renal transplantation. Clin. Transpl. 2006, 20:85-90.
73. Gabrielli A., Marrozzini C., Candela M., Ferretti R.M., Recchioni A., Binetti G.F., et al. Prognostic significance of basement membrane antigens and of soluble interleukin 2 receptor serum concentrations in heart transplant rejection. Cardiologia 1994, 39:481-486.
74. Rasool R., Yousuf Q., Masoodi K.Z., Bhat I.A., Shah A.Z., Wani I.A., et al. Relationship between serum soluble interleukin-2 receptor and renal allograft rejection: a hospital based study in Kashmir valley. Int. J. Organ Transpl. Med. 2015, 6:8-13.
75. Granot E., Tarcsafalvi A., Emre S., Sheiner P., Guy S., Schwartz M.E., et al. Th1/Th2 cytokines and ICAM-1 levels post-liver transplant do not predict early rejection. Mediat. Inflamm. 2000, 9:35-38.
76. Leicht S., Shipkova M., Klett C., Gert H., Altrock E., Wilhelm J., et al. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation. Clin. Biochem. 2013, 46:1383-1388.
77. Rouschop Kasper M.A., Roelofs Joris J.T.H., Rowshani A.T., Leemans J.C., van der Poll Tom, ten Berge Ineke J.M., et al. Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection. Nephrol. Dial. Transplant. 2005, 20:2248-2254.
78. Wang Y., Zhang Y., Li G., Tang Z., Zhou Y., Zhu Z., et al. Correlation of CD95 and soluble CD95 expression with acute rejection status of liver transplantation. World J. Gastroenterol. 2005, 11:1700-1704.
79. Yunihastuti E., Lee S., Gani R.A., Saraswati H., Sundaru H., Lesmana L.A., et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clin. Immunol. 2011, 139:32-39.
80. Streitz M., Miloud T., Kapinsky M., Reed M.R., Magari R., Geissler E.K., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transl. Res. 2013, 2:17.
81. Geissler E.K., Tullius S.G., Chong A.S. Establishment of a global virtual laboratory for transplantation: a symposium report. Transplantation 2015, 99:381-384.
82. Chang D.M., Ding Y.A., Kuo S.Y., Chang M.L., Wei J. Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol. Investig. 1996, 25:13-21.
83. Sindhi R., Manavalan J.S., Magill A., Suciu-Foca N., Zeevi A. Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+ CD28- T-suppressor cells. Hum. Immunol. 2005, 66:252-257.
84. Sindhi R., Magill A., Bentlejewski C., Abdullah A., Tresgaskes M., Seward J., et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am. J. Transplant. 2005, 5:96-102.
85. Roberti I., Reisman L. Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry - correlation with clinical outcome. Transplantation 2001, 71:1317-1320.
86. Ashokkumar C., Bentlejewski C., Sun Q., Higgs B.W., Snyder S., Mazariegos G.V., et al. Allospecific CD154+ B cells associate with intestine allograft rejection in children. Transplantation 2010, 90:1226-1231.
87. Crosbie O.M., Norris S., Hegarty J.E., O'Farrelly C. T lymphocyte subsets and activation status in patients following liver transplantation. Immunol. Investig. 1998, 27:237-241.